How should I evaluate and manage an adult presenting with atrial fibrillation, including assessment of hemodynamic stability, stroke risk, anticoagulation, and rate versus rhythm control?

Management of Atrial Fibrillation

Immediate Hemodynamic Assessment

Perform immediate synchronized electrical cardioversion (≥200 J biphasic) without awaiting anticoagulation in any patient with hemodynamic instability—defined as systolic blood pressure <90 mmHg, altered mental status, acute pulmonary edema, ongoing chest pain, or cardiogenic shock. 1, 2 Concurrent intravenous heparin bolus should be administered if feasible. 2

Before administering any medication, examine the ECG for delta waves (pre-excitation) suggesting Wolff-Parkinson-White syndrome. 1, 2, 3 If pre-excitation is present, all AV-nodal blocking agents (beta-blockers, calcium-channel blockers, digoxin, adenosine, amiodarone) are absolutely contraindicated because they can accelerate ventricular rate through the accessory pathway and precipitate ventricular fibrillation. 1, 2, 3 In stable WPW patients with AF, administer IV procainamide (15 mg/kg over 20–30 min) or IV ibutilide; if unstable, proceed directly to cardioversion. 1, 2, 3

Stroke Risk Assessment and Anticoagulation

Calculate the CHA₂DS₂-VASc score immediately: congestive heart failure (1 point), hypertension (1), age ≥75 years (2), diabetes (1), prior stroke/TIA/thromboembolism (2), vascular disease (1), age 65–74 years (1), female sex (1). 2

Initiate oral anticoagulation for all patients with a CHA₂DS₂-VASc score ≥2 (men) or ≥3 (women). 2 Direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran) are preferred over warfarin in all patients except those with mechanical heart valves or moderate-to-severe mitral stenosis, because DOACs reduce intracranial hemorrhage risk and have predictable pharmacokinetics. 2 When warfarin is required, target INR 2.0–3.0 with weekly monitoring during initiation and monthly checks once stable. 1, 2

Anticoagulation must be continued indefinitely based on the CHA₂DS₂-VASc score, regardless of whether sinus rhythm is restored. 2 In the AFFIRM trial, 72% of strokes occurred in patients who had discontinued anticoagulation or had subtherapeutic INR (<2.0). 2

Rate-Control Strategy

Patients with Preserved Left Ventricular Ejection Fraction (LVEF >40%)

First-line agents are intravenous beta-blockers (metoprolol 2.5–5 mg IV over 2 min, repeat every 5 min up to three doses) or non-dihydropyridine calcium-channel blockers (diltiazem 0.25 mg/kg IV over 2 min, then infusion 5–15 mg/h). 1, 2, 3 Both are equally effective, with diltiazem achieving slightly faster rate control (onset 2–7 min vs. 5 min for metoprolol). 2, 3

Beta-blockers are preferred in acute coronary syndrome, thyrotoxicosis, or chronic stable heart failure because of proven mortality benefit. 2, 3 Diltiazem is preferred in chronic obstructive pulmonary disease or active bronchospasm when beta-blockers are contraindicated. 1, 2, 3

Target a lenient resting heart rate <110 bpm initially; pursue stricter control (<80 bpm) only if symptoms persist despite achieving the lenient goal. 2 Assess heart rate during exertion, not solely at rest, because many patients have inadequate control during activity despite acceptable resting rates. 2

Patients with Reduced Ejection Fraction (LVEF ≤40%) or Heart Failure

Use only beta-blockers (bisoprolol, carvedilol, long-acting metoprolol) and/or digoxin; avoid diltiazem and verapamil because of negative inotropic effects that may precipitate hemodynamic collapse. 1, 2, 3 Beta-blockers remain first-line even in reduced-EF heart failure because of mortality benefit. 2, 3

Digoxin dosing: 0.25 mg IV, repeat up to cumulative 1.5 mg/24 h. 2 Digoxin alone is ineffective for acute rate control during sympathetic surges (fever, sepsis, exercise) and should not be used as monotherapy. 1, 2, 3

Combination Therapy When Monotherapy Fails

If adequate rate control is not achieved within 4–7 days of optimal monotherapy, add digoxin (0.0625–0.25 mg daily) to the beta-blocker or calcium-channel blocker. 2 Combination therapy provides superior heart-rate control at rest and during exercise compared with either agent alone. 1, 2 Monitor closely for bradycardia when combining agents. 2

Never combine beta-blocker with calcium-channel blocker except under specialist supervision due to risk of severe bradycardia and heart block. 2, 3

Rhythm-Control Considerations

Rate control plus anticoagulation is as effective as rhythm control for reducing mortality and cardiovascular events in most patients, with fewer adverse effects and hospitalizations. 1, 2 Rhythm control does not reduce mortality and is associated with higher hospitalization rates and drug-related adverse events. 1, 2

Consider rhythm-control strategies for: (1) patients who remain symptomatic despite adequate rate control, (2) younger patients (<65 years) with new-onset AF, (3) those with rate-related cardiomyopathy, or (4) hemodynamically unstable patients. 2

Cardioversion Protocol

For AF lasting >48 hours or of unknown duration, provide therapeutic anticoagulation for ≥3 weeks before elective cardioversion and continue for ≥4 weeks afterward. 1, 2 Alternatively, perform transesophageal echocardiography to exclude left-atrial thrombus; if negative, proceed with cardioversion after initiating heparin. 1, 2

Antiarrhythmic Drug Selection (Based on Cardiac Structure)

No structural heart disease (normal LVEF, no coronary disease, no LV hypertrophy): Flecainide, propafenone, or sotalol are first-line agents. 2 These must be avoided in patients with ischemic or structural heart disease. 2

Coronary artery disease with LVEF >35%: Sotalol is preferred; requires hospitalization with continuous ECG monitoring for ≥3 days and dose adjustment for renal function. 2

Heart failure or LVEF ≤40%: Amiodarone or dofetilide are the only safe options because other antiarrhythmics carry high pro-arrhythmic risk. 2 Amiodarone is reserved as second- or third-line therapy because of significant extracardiac toxicity (pulmonary fibrosis, hepatic injury, thyroid dysfunction). 2

Special Clinical Scenarios

Secondary AF (Sepsis, Pneumonia, Pulmonary Embolism)

Aggressive treatment of the underlying condition (antibiotics for pneumonia, source control for sepsis, thrombolysis for massive PE) is the first-line intervention and frequently resolves rapid ventricular response without additional rate-control drugs. 3, 4 A heart rate around 150 bpm can represent an appropriate physiologic response to fever and infection; suppressing this response may impair cardiac output. 3, 4

Pharmacologic rate control should be initiated only if the patient develops hemodynamic instability or if the ventricular rate remains >110 bpm after the fever has resolved. 3, 4

Postoperative AF

Prophylactic oral beta-blocker postoperatively reduces the incidence of new-onset AF unless contraindicated. 1 If postoperative AF occurs, achieve rate control with AV-node-blocking agents. 1

Common Pitfalls to Avoid

• Do not discontinue anticoagulation solely because sinus rhythm has been restored; stroke risk is determined by CHA₂DS₂-VASc score, not rhythm status. 2
• Do not rely on digoxin alone for acute rate control; it is ineffective during sympathetic surges. 1, 2, 3
• Do not use calcium-channel blockers in patients with LVEF ≤40% or decompensated heart failure. 1, 2, 3
• Do not assess heart rate solely at rest; always evaluate during exertion. 2
• Do not cardiovert AF when hypotension is primarily due to septic or obstructive shock; treat the underlying shock first. 4
• Do not use aspirin alone for stroke prevention; oral anticoagulants are superior. 2, 5